News
STE
232.79
+2.30%
5.23
Steris Price Target Maintained With a $265.00/Share by JMP Securities
Dow Jones · 7h ago
JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target
Benzinga · 7h ago
Buy Rating Affirmed for Steris on Strategic Divestiture and Strong Financial Outlook
David Turkaly from JMP Securities reiterated a Buy rating on Steris with a price target of $265.00. The company's recent divestiture of its dental segment for $800 million is expected to streamline the business. Turkaly is an analyst with an average return of -2.0% and a 40.61% success rate.
TipRanks · 21h ago
STERIS’ Quarterly Earnings Preview: What You Need to Know
STERIS plc (STE) provides infection prevention products and services. The company is expected to announce its fiscal first-quarter earnings for 2025 after the market closes on Tuesday, Aug. 6. STE stock has underperformed the S&P 500’s 15.2% gains on a YTD basis.
Barchart · 2d ago
Piper Sandler Sticks to Its Hold Rating for Steris (STE)
TipRanks · 2d ago
STERIS to Host a Conference Call for Fiscal 2025 First Quarter Financial Results on August 7, 2024
STERIS plc will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone.
Barchart · 3d ago
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
NASDAQ · 3d ago
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Seeking Alpha · 3d ago
STERIS plc (NYSE:STE) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
STERIS' (NYSE:STE) stock increased by 8.9% over the past three months. STERIS has a return on equity of 8.8% and is similar to the industry average of 11%. The company's net income growth over the last five years is flat. The company retains most of its profits and is reinvesting them in the business. Its high ROE suggests the company is undervalued by the market.
Simply Wall St · 4d ago
Weekly Report: what happened at STE last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at STE last week (0708-0712)?
Weekly Report · 07/15 09:00
STERIS (STE) AST Business Expands, New Offerings Aid Growth
NASDAQ · 07/11 13:10
STE Crosses Below Key Moving Average Level
NASDAQ · 07/09 15:08
Should You Hold STERIS (STE) Stock Now? Here's What to Consider
NASDAQ · 07/08 11:29
Weekly Report: what happened at STE last week (0701-0705)?
Weekly Report · 07/08 09:00
When Should You Buy STERIS plc (NYSE:STE)?
STERIS plc (NYSE:STE) is currently trading at a low price of US$217 on the NYSE. The large-cap company is expected to grow its profit by 62% over the next few years. The intrinsic value of the stock is $315.27, but STERIS is currently undervalued at $217. The future growth of the company is not fully reflected in the current share price. It may be a great time to buy STE to increase your holdings.
Simply Wall St · 07/04 11:28
Weekly Report: what happened at STE last week (0624-0628)?
Weekly Report · 07/01 09:00
Weekly Report: what happened at STE last week (0617-0621)?
Weekly Report · 06/24 09:01
STERIS (STE) Gains From New Offerings, Macro Issues Ail
NASDAQ · 06/17 11:02
Weekly Report: what happened at STE last week (0610-0614)?
Weekly Report · 06/17 09:00
More
Webull provides a variety of real-time STE stock news. You can receive the latest news about Steris Plc through multiple platforms. This information may help you make smarter investment decisions.
About STE
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.